HCM

HUTCHMED (China)
HCM

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
£1.88B
EV
£1.29B
Shares Outstanding
854.89M
Beta
0.60

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
£4.91
P/E 2025E
17.48x
P/Revenue 2025E
4.00x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About HUTCHMED (China) Limited

gainify
HCM

HUTCHMED (China) Limited

HCM

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of no...

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Su, Wei-Guo

Employees

1,811

IPO Date

2006-05-19

Headquarters

Cheung Kong Center, 48th floor, 2 Queen's Road Central, Hong Kong Hong Kong

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.